Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Ocul Immunol Inflamm
; 29(3): 472-478, 2021 Apr 03.
Article
em En
| MEDLINE
| ID: mdl-32845738
ABSTRACT
Background/aims:
To report our five-year experience on vitreoretinal lymphoma (VRL) as a single-center tertiary hospital.Methods:
The ophthalmic, cytopathology, and onco-hematologic records of patients with VRL consecutively seen from 2014 to 2019 were reviewed.Results:
Fifty-nine eyes of 31 patients with large B-cell VRL were included. Eighty-one percent has developed central nervous system lymphoma at the end of follow-up. Several different imaging findings were noted, including vitritis, leopard spot appearance, Bruch's membrane/RPE infiltrations, and ellipsoid zone disruption. A variable combination of MYD88-L265P mutation in the aqueous and/or in the vitreous and positive cytology/histology allowed to reach a definite diagnosis in all the patients. Therapies included intravitreal injections of methotrexate and rituximab, systemic chemotherapy, pan-encephalic radiotherapy, and hematopoietic stem cell transplantation.Conclusion:
No definite guidelines exist for VRL management. It is crucial to collect as much data as possible from tertiary referral hospitals, which suitably manage a conspicuous number of VRL patients.Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Corpo Vítreo
/
Linfoma não Hodgkin
/
Linfoma Difuso de Grandes Células B
/
Neoplasias do Sistema Nervoso Central
/
Neoplasias da Retina
/
Linfoma Intraocular
Idioma:
En
Ano de publicação:
2021
Tipo de documento:
Article